Introduction {#s1}
============

The dorsomedial hypothalamus (DMH) is a brain structure adjacent to the third ventricle, which is located caudal and ventral to the paraventricular nucleus of the hypothalamus (PVN). Its lateral portion is adjacent to both the fornix and the lateral hypothalamic area. The DMH is subdivided into two distinct portions: a diffuse and a compact zone ([@B32]).

The involvement of DMH in cardiovascular regulation has been well evidenced in the literature. Electrical stimulation or chemical inhibition of this area has been reported to increase blood pressure (BP) and heart rate (HR) in anesthetized rats ([@B39]; [@B22]). In addition, the DMH also participates in neuroendocrine regulation, because its chemical stimulation increases the release of adrenocorticotropic hormone (ACTH), as well as the expression of *c-fos* protein in the PVN, causing a response similar to that observed under stressful situations ([@B2]; [@B30]; [@B36]). The PVN is well recognized as an important structure for the integration of neuroendocrine and autonomic responses; PVN neuroendocrine parvocellular neurons modulate ACTH release, while PVN magnocellular neurons synthesize vasopressin and oxytocin ([@B23]). Emotional stress is well recognized as an integrated physiological response of the neuroendocrine and autonomic nervous systems, and has been related to the development of different pathologies in humans, such as hypertension, arrhythmias, myocardial infarction, as well as psychiatric disorders ([@B15]; [@B12]; [@B29]; [@B31]). The RS is defined in the literature as an animal stress model, which causes sustained BP and HR increase, reduction in tail temperature, activation of the hypothalamic-pituitary adrenal axis (HPA), and has been extensively used to study the autonomic and neuroendocrine responses to stress ([@B3]; [@B20]; [@B17]; [@B4]; [@B28]; [@B5]).

The DMH is an important center of regulation of the emotional response to stress ([@B10]). It was demonstrated that foot-shock stress activates neuronal projections from the DMH to PVN ([@B21]), and that local pharmacological manipulations alter the cardiovascular response triggered by stress ([@B43]), including the restraint stress model (RS) ([@B41]). Although there is this study about the involvement of DMH on RS-related responses ([@B41]), the role of the DMH in the modulation of different responses caused by acute RS it is not well established in the literature. In this context, we hypothesize that DMH modulates autonomic (BP, HR, and tail temperature) and neuroendocrine responses (corticosterone, vasopressin, and oxytocin release) both under rest conditions as well as during stressful situations.

For this purpose, we pretreated the DMH of unanesthetized rats with the nonspecific and acute synaptic blocker CoCl~2~ ([@B19]; [@B24]), and analyzed the effect of its inactivation on the autonomic and neuroendocrine function under rest and stressful conditions.

Experimental Procedures {#s2}
=======================

Animals {#s2_1}
-------

All experimental procedures were carried out following protocols approved by the University of São Paulo Animal Ethical Committee (n° 221/2018), which complies with the European Communities Council Directive of September 22, 2010 (82,010/63/EU). Male Wistar rats weighing 250--280g were used. Animals were housed in plastic cages in a temperature-controlled room at 25°C in the Animal Care Unit of the Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil. Animals were kept under a 12--12 h light-dark cycle (lights on between 06:00 and 18:00 h). Animals had free access to water and standard laboratory food. The rats were transported to the experimental room and remained in their own cages until being subjected to restraint. Experiments were performed during the morning period (08:00 to 12:00) in order to minimize possible circadian rhythm interferences.

Surgical Procedures {#s2_2}
-------------------

Seven days before the experiment, animals were anesthetized with 10% ketamine--2% xylazine (0.09 ml/100 g body weight, i.p.), and their heads were fixed to a stereotaxic apparatus (Stoelting, USA). After local anesthesia of the scalp with 2% lidocaine, the skull was surgically exposed and trepanned with a dental drill at 1.9 mm from the medial line and 7.2 mm anterior to the interaural line ([@B32]). Stainless steel guide cannulas (26 G) were implanted bilaterally into the DMH based on the rat brain atlas of [@B32]: AP = -3.1 mm anterior to the interaural line, L = 2.3 mm from the medial suture, V = -7.2 mm from the skull at a 12° angle. The incisor bar was positioned at -3.2 mm. Guide cannulas were implanted 1 mm above the intended injection sites and fixed to the skull with a metal screw and dental cement. Stainless wires with 0.2 mm outer diameter and 15 mm in length were introduced into the cannulas to avoid occlusion during the recovery period after surgery. After the surgery, animals were treated with poly-antibiotic, with streptomycins and penicillins (Pentabiotico^®^, FontouraWyeth, Brazil, 80.000 UI i.m.) to prevent infection and the non-steroidal anti-inflammatory flunixin meglumine (Banamine^®^, Schering Plough, RJ, Brazil) for post-operation analgesia. One day before the experiment, a polyethylene catheter was inserted into the femoral artery under anesthesia, for mean arterial pressure (MAP) and HR recording. The catheter was exposed on the dorsum of the animals and fixed to the skin. Cardiovascular and temperature recordings were performed in their own cages or during the session of restraint. After surgical procedures the animals received flunixin meglumine (Banamine^®^, Schering Plough, Brazil; 2.5 mg/kg s.c.).

Cardiovascular Recording {#s2_3}
------------------------

On the day of the experiment, the arterial catheters were connected to a pressor transducer. The pulsatile arterial pressure (PAP) was recorded using an amplifier (model 7754A, Hewlett Packard, USA) coupled to a computerized system (MP100A, Biopac, USA). MAP and HR values were derived from PAP data using the Acknowledge III software (Biopac, USA). The HR (beats/min, bpm) was calculated from PAP peak intervals integrated every 6 s.

Tail Temperature Measurement {#s2_4}
----------------------------

Tail temperature was measured throughout the entire rat's tail using a thermal camera (Multi-Purpose Thermal Imager IRI 4010; Infrared Integrated Systems Ltd., USA), with the camera positioned at a distance 50 cm above the tail. Tail temperature value was averaged from ten points distributed throughout the tail's length.

Acute Restraint Stress {#s2_5}
----------------------

Animals were subjected to the session of restraint by placing each animal into a plastic cylindrical tube (6.5 cm diameter, 15 cm length), ventilated by holes (1 cm diameter) that comprised approximately 20% of the tube surface. Restraint session lasted 60 min. Animals were subjected to only one session of restraint, in order to avoid habituation.

Neuroendocrine Protocol and Plasma Corticosterone, Vasopressin, and Oxytocin Measurements {#s2_6}
-----------------------------------------------------------------------------------------

The neuroendocrine experiments were performed using the same protocol of RS. Briefly, rats were subjected to stereotaxic surgery and recovered for five days. One day before the experiment, rats were placed in individual home-cages and transported to the experimental room. During the experimental period, rats remained in their own cages until being subjected to restraint. Rats received one microinjection of CoCl~2~ or vehicle bilaterally into the DMH, and 10 min after, were subjected to one session of 0, 20, or 40 min of RS, in order to evaluate the time-course of the neuroendocrine response. Immediately after the RS session, rats were decapitated and the blood samples were collected from the trunk in heparinized tubes (10µl/ml). The plasma samples were separated by centrifugation (3,000 rpm for 15 min at 4°C) and stocked at -20°C. Plasma corticosterone, vasopressin and oxytocin were measured by radioimmunoassay according to established techniques, previously described in detail ([@B35]).

Drugs and Solutions {#s2_7}
-------------------

CoCl~2~ (1 mM/100 nl) (Sigma, USA) was dissolved in artificial cerebrospinal fluid (ACSF), which had the following composition: 100 mM NaCl, 2 mM Na~3~PO~4~, 2.5 mM KCl, 1mM MgCl~2~, 27 mM NaHCO~3~, 2.5 mM CaCl~2~, pH 7.4.Urethane (Sigma, USA) was dissolved in saline (0,9% NaCl). Flunixin meglumine (Banamine^®^, Schering Plough, Brazil) and the poly-antibiotic preparation of streptomycins and penicillins (Pentabiotico^®^, Fontoura-Wyeth, Brazil) were used as provided.

Drug Microinjection Into the DMH {#s2_8}
--------------------------------

Bilateral injections were performed in a volume of 100 nl using a 1-µl syringe (7001KH; Hamilton, USA) connected to a microinjection needle (gauge G 33- Small Parts, USA) through a piece of PE-10 polyethylene tubing. The microinjection needle was 1 mm longer than the guide cannula. Microinjections were performed within a 5 s period. After microinjection, the needle was left in the guide cannula for 1 min before being removed. Drugs were prepared before the experiments and stored at -20°C. On the day of the experiment, drugs were thawed and kept on ice during experimental procedures.

Histological Determination of Microinjection Sites {#s2_9}
--------------------------------------------------

At the end of experiments, animals were anesthetized with urethane (1.25 g/kg i.p.) and 100 nl of 1% Evans blue dye was injected into the brain as a marker of the injection site. They were then subjected to intracardiac perfusion with 0.9% NaCl followed by 10% formalin. Brains were removed and post-fixed for 48 h at 4°C, and serial 40 µm-thick sections were cut with a cryostat (CM1900, Leica, Germany). Sections were stained with 1% cresyl violet, for light microscopy analysis. The placement of the microinjection needles was determined by analyzing serial sections, and was identified according to the rat brain atlas of [@B32].

Data Analysis {#s2_10}
-------------

Statistical analysis was performed using the Prism software. Data were expressed as means ± SEM. The raw basal values of MAP and HR was represented by the total mean of the ten points before and after the pretreatment. The raw basal values of tail temperature (TT) was represented by the total mean of three points before and after the pretreatment. The raw means of the cardiovascular values were represented by the total mean of sixty points during RS. The raw mean of the TT was represented by the total mean of seven points during RS. The Student's paired t test was used to compare the raw basal values of MAP, HR, and TT before and after treatments. The Student's unpaired t test was used to compare the raw basal values and RS average values between ACSF and CoCl~2~-treated animals. The changes from baseline within the groups were analyzed using the one-way ANOVA followed by Dunnet´s *post-hoc* test comparing each point to the first minute of the time-course (time -20 min). The time-course of changes in ΔMAP, ΔHR, and ΔTT was analyzed using repeated measures two-way ANOVA with treatment (vehicle and drug) as a main factor, and time as a repeated measurement. Treatment effects on RS-related responses (mean ΔMAP, ΔHR, and ΔTT) were further compared to the vehicle control using the Fisher's *post-hoc* test. The neuroendocrine response was analyzed using the total mean of four time-course points, (-10, 0, 20, and 40 min) using two-way ANOVA followed by Fisher's *post-hoc* test, with treatment (vehicle or CoCl~2~) and condition (home-cage or RS) as main factors. The unpaired t Student´s test with Welch´s correction was used to compare the treated group with the control group on the same conditions (home-cage or RS). Values of p \< 0.05 were assumed as statistically significant differences between the groups. The effect sizes was calculated for the main effects using Stata 14 software and the data were expressed as Cohen's *d* value for t tests and as omega squared (Ω^2^) for ANOVA.

Results {#s3}
=======

A diagrammatic representation showing the bilateral sites of microinjection in the DMH of all animals used is presented in [**Figure 1**](#f1){ref-type="fig"}.

![A diagrammatic representation based on the rat brain atlas of [@B32] indicating DMH microinjections sites (filled circles). The number of points represented can be fewer than the real number of animals used in the experiment due to overlap. DMH, dorsomedial hypothalamus; f, fornix; 3V, third ventricle; IA, interaural.](fphar-10-01547-g001){#f1}

Effect of Cocl~2~ Microinjection Into the DMH on the Autonomic Responses in Rats At the Home-Cage. {#s3_1}
--------------------------------------------------------------------------------------------------

The analysis of raw basal values mean of ten points before and those after the pretreatment (-20 to -11 min *versus* -10 to -1 min) using the Student's paired t test indicated that the microinjection of ACSF (100 nl) (n = 4) into the DMH did not affect the MAP (t = 1.5, P = 0.2), HR (t = 1.6, P = 0.2) and TT (t = 0.5, P = 0.6), when compared the basal values before and after the ACSF-treatment. The microinjection of CoCl~2~ (1 nM/100 nl) (n = 4) into the DMH significantly increased the MAP (t = 4.6, P = 0.01, Cohen's *d* = -1.00) and HR (t = 4.3, P = 0.02, Cohen's *d* = -1.56), when compared the basal values before and after the CoCl~2~-treatment, without affecting the TT one (t = 0.4, P = 0.6) ([**Table 1**](#T1){ref-type="table"}).

###### 

Raw basal values of mean arterial pressure (MAP), heart rate (HR) and tail temperature (TT) before and after the microinjection of CoCl~2~ into the DMH in rats under the home-cage situation.

  CoCl~2~ (mM/100nl)   n   MAP           HR            TT                                                                                          
  -------------------- --- ------------- ------------- ----- -------- -------------- -------------- ----- -------- ------------ ------------ ----- -----
  **0**                4   106.7 ± 1.6   108.6 ± 1.3   1.5   0.2      364.8 ± 12.4   375.6 ± 13.7   1.6   0.2      26.7 ± 0.7   27.5 ± 1.0   0.5   0.6
  **1**                4   99.9 ± 3.9    108.8 ± 4.7   4.6   0.01\*   373.6 ± 22.3   478.0 ± 41.4   4.3   0.02\*   26.2 ± 0.8   25.9 ± 0.7   0.4   0.6

Values are raw mean and ± SEM. **\***significant difference before and after treatment, Student's paired t test, P \< 0.05. No significant difference was found in the MAP basal values of CoCl~2~-treated animals when compared to the ACSF one (0 versus 1) before (t = 1.5, P = 0.1) and after (t = 0.04, P = 0.9) pretreatment into DMH. No significant difference was found in the HR basal values of CoCl~2~-treated animals when compared to the ACSF one (0 versus 1) before (t = 0.3, P = 0.7) and after (t = 2.3, P = 0.08) pretreatment into DMH. No significant difference was found in the TT basal values of CoCl~2~- treated animals when compared to the ACSF one (0 versus 1) before (t = 0.5, P = 0.6) and after (t = 1.3, P = 0.2) pretreatment into DMH. Student's unpaired t test), P \> 0.05.

The one-way ANOVA indicated that the microinjection of ACSF (100 nl) (n = 4) into the DMH did not affected the ΔMAP (F~80,~ ~243~ = 0.60, P = 0.99, ω^2^ = 0) and ΔHR (F~80,~ ~243~ = 0.75, P = 0.92) time-course within the group, when comparing each time point to the first minute (time -20 min). The one-way ANOVA indicated that the microinjection of CoCl~2~ (1 mM/100 nl) (n = 4) into the DMH increased the ΔMAP (F ~80,~ ~243~ = 1.41, P = 0.02, ω^2^ = 0.09) and ΔHR (F~80,~ ~243~ = 2.15, P \< 0.0001, ω^2^ = 0.22) time-course within the group, when comparing each time point to the first minute (time -20 min). The Dunnet's *post-hoc* point-to-point test is presented in the figure ([**Figure 2**](#f2){ref-type="fig"}).

![Mean arterial pressure (ΔMAP), heart rate (ΔHR) and tail temperature (Δ tail temperature) changes over time in rats during rest at home-cage with the DMH pretreated with either vehicle (ACSF) (open circles, n = 4) or CoCl~2~ (1 mM/100 nl) (filled circles, n = 4). Rats were treated at time -10 min. Points represent the mean and bars the SEM; arrow indicates the treatment; \*significant difference between time-points from CoCl~2~-treated animals and vehicle-treated (ACSF), (two-way ANOVA followed by Fisher's *post-hoc* test, P \< 0.05). ^+^significant difference between the indicated point and the basal value at time -20 min in CoCl~2~-treated group (one-way ANOVA followed by Dunnet's *post-hoc* test, P \< 0.05).](fphar-10-01547-g002){#f2}

The two-way ANOVA indicated that the microinjection of CoCl~2~ (1 mM/100 nl) (n = 4) into the DMH significantly increased the ΔMAP (treatment: F ~(1,~ ~486)~ = 48.87, P \< 0.0001, ω^2^ = 0.086; time: F ~(80,~ ~486)~ = 1.196, P = 0.13,; interaction: F ~(80,~ ~486)~ = 1.03, P = 0.40) and ΔHR (treatment: F ~(1,~ ~486)~ = 228.7, P \< 0.0001, ω^2^ = 0.318; time: F ~(80,~ ~486)~ = 2.080, P \< 0.0001, ω^2^ = 0.132; interaction: F ~(80,~ ~486)~ = 1.757, P = 0.0002, ω^2^ = 0.096) parameters, when compared with ACSF-treated animals (n = 4) ([**Figures 2A, B**](#f2){ref-type="fig"}). A representative figure of the cardiovascular changes caused by CoCl~2~ microinjection under the home-cage situation is shown in [**Figure 4A**](#f4){ref-type="fig"}. Under rest condition at home-cage, the microinjection of CoCl~2~ (1 mM/100 nl) did not affect the ΔTT (treatment: F ~(1,~ ~78)~ = 2.59, P = 0.11; time: F ~(12,78)~ = 0.56, P = 0.86; interaction: F ~(12,~ ~78)~ = 0.12, P = 0.99) when compared with the ACSF-treated animals The Fisher's *post-hoc* point-to-point test is presented in the figure. ([**Figure 2C**](#f2){ref-type="fig"}).

Effect of Cocl~2~ Microinjection Into the DMH on the Cardiovascular Response in Rats Subjected to RS {#s3_2}
----------------------------------------------------------------------------------------------------

The analysis of raw basal values mean of the ten points before and those after the pretreatment (-20 to -11 min *versus* -10 to -1 min) by the Student's paired t test indicated that the microinjection of ACSF (100 nl) (n = 5) into the DMH did not affected the MAP (t = 1.9, P = 0.1), HR (t = 1.2, P = 0.2) and TT (t = 1.5, P = 0.1), when compared the basal values before and after the ACSF-treatment. The microinjection of CoCl~2~ (1 mM/100 nl) (n = 5) into the DMH significantly increased the MAP (t = 3.3, P = 0.02, Cohen's *d* = -0.66) and HR (t = 3.7, P = 0.01, Cohen's *d* = -1.85), when compared the basal values before and after the CoCl~2~-treatment, without affecting the TT one (t = 0.4, P = 0.6) ([**Table 2**](#T2){ref-type="table"}).

###### 

Raw basal values of mean arterial pressure (MAP), heart rate (HR) and tail temperature (TT) before and after the microinjection of CoCl~2~ into the DMH in rats subjected to RS.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Baseline values before RS                                                                                                                                                                                                         
  ---------------------------------- --- ----------------------------- ------------- ---------- ---------------------------- -------------- -------------- --------------------------- ------------ ------------ ------------ ----- -----
  **0**                              5   103.0 ± 2.9                   101.6 ± 2.7   1.9        0.1                          373.3 ± 14.2   384.3 ± 6.7    1.2                         0.2          30.6 ± 0.7   29.6 ± 0.7   1.5   0.1

  **1**                              5   93.1 ± 4.9                    100.9 ± 5.4   3.3        0.02**\#**                   349.3 ± 8.0    415.0 ± 21.1   3.7                         0.01**\#**   29.9 ± 1.1   30.2 ± 1.6   0.4   0.6

  **Autonomic response during RS**                                                                                                                                                                                                  

  **CoCl~2~ (mM/100nl)**             n   **MAP**                       **HR**        **TT**                                                                                                                                         

                                         **RS average ± SEM (mmHg)**   **t=**        **P\<**    **RS average ± SEM (bpm)**   **t=**         **P\<**        **RS average ± SEM (°C)**   **t=**       **P\<**                         

  **0**                              5   110.5 ± 0.5                   \             \          442.7 ± 2.6                  \              \              27.5 ± 0.2                  \            \                               
                                                                       16.9          0.0001\*                                6.7            0.0001\*                                   7.5          0.0001\*                        

  **1**                              5   100.3 ± 0.3                                            421.7 ± 1.6                                                30.1 ± 0.1                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are raw mean and ± SEM. **\#**significant difference before and after treatment, Student's paired t test, P \< 0.05. No significant difference was found in the MAP basal values of CoCl~2~-treated animals when compared to the ACSF one (0 versus 1) before (t = 1.7, P = 0.1) and after (t = 0.10, P = 0.9) pretreatment into DMH. No significant difference was found in the HR basal values of CoCl~2~-treated animals when compared to the ACSF one (0 versus 1) before (t = 1.4, P = 0.1) and after (t = 1.4, P = 0.2) pretreatment into DMH. No significant difference was found in the TT basal values of CoCl~2~- treated animals when compared to the ACSF one (0 versus 1) before (t = 0.5, P = 0.6) and after (t = 0.3, P = 0.7) pretreatment into DMH. Student's unpaired t test), P \> 0.05. \*significant difference when compared ACSF-RS and CoCl~2~-RS groups, Student's unpaired t test, P \< 0.05.

The Student's unpaired t test indicated that the microinjection of CoCl~2~ reduced the pressor (t = 16.9, P \< 0.0001, Cohen's *d* = 24.7) and tachycardic (t = 6.7, P \< 0.0001, Cohen's *d* = 9.7) responses evoked by RS and impaired the reduction in TT (t = 7.5, P \< 0.0001, Cohen's *d* = -16.4), when compared to the ACSF-stressed group ([**Table 2**](#T2){ref-type="table"}).

The one-way ANOVA indicated that the ACSF-RS group (100 nl) (n = 5) increased ΔMAP (F~80,~ ~324~ = 3.48, P \< 0.0001, ω^2^ = 0.33) and ΔHR (F~80,~ ~324~ = 2.52, P \< 0.0001, ω^2^ = 0.23) time-course within the group, when comparing each time point to the first minute (time -20 min). The one-way ANOVA indicated that the CoCl~2~-RS group (1 mM/100 nl) increased the ΔMAP (F~80,~ ~324~ = 3.91, P \< 0.0001, ω^2^ = 0.36) and ΔHR (F~80,~ ~324~ = 3.30, P \< 0.0001, ω^2^ = 0.31) time-course within the group, when comparing each time point to the first minute (time -20 min). The Dunnet's *post-hoc* point-to-point test is presented in the figure ([**Figure 3**](#f3){ref-type="fig"}).

![Mean arterial pressure (ΔMAP), heart rate (ΔHR) and tail temperature (Δ tail temperature) changes over time during acute restraint stress in rats with DMH pretreated with vehicle (ACSF) (open circles, n = 5) or CoCl~2~ (1 mM/100 nl) (filled circles, n = 5). Rats were subjected to acute restraint stress session at time 0 min. Points represent the mean and bars the SEM; arrow indicates the treatment; \*significant difference between CoCl~2~-treated animals and the vehicle (ACSF) group, (two-way ANOVA followed by Fisher's *post-hoc* test, P \< 0.05). ^\#^significant difference between the indicated point and the basal value at time -20 min in ACSF-treated group, ^+^significant difference between the indicated point and the basal value at time -20 min in CoCl~2~-treated group (one-way ANOVA followed by Dunnet's *post-hoc* test, P \< 0.05).](fphar-10-01547-g003){#f3}

The two-way ANOVA indicated that the microinjection of CoCl~2~ (1 mM/100 nl) (n = 5) into the DMH reduced the pressor (ΔMAP) (treatment: F(~1,~ ~648)~ = 5.839, P = 0.01, ω^2^ = 0.007; time: F~(80,~ ~648)~ = 4.914, P \< 0.0001, ω^2^ = 0.30); interaction: F~(80,~ ~648)~ = 1.13, P = 0.04, ω^2^ = 0.01) and the tachycardic (ΔHR) (treatment: F (~1,~ ~648~) = 13.54 P = 0.0003, ω^2^ = 0.018; time: F ~(80,~ ~648)~ = 6.239, P \< 0.0001, ω^2^ = 0.365); interaction: F ~(80,~ ~648)~ = 1,057, P = 0.35) responses during the RS session, when compared to the ACSF-stressed group (n = 5). A representative figure of the cardiovascular changes caused by RS is shown in [**Figure 4B**](#f4){ref-type="fig"}. In addition, DMH pretreatment with CoCl~2~ (1 mM/100 nl) significantly impaired the reduction of ΔTT (treatment: F~(1,~ ~104)~ = 63.49, P \< 0.0001, ω^2^ = 0.373; time: F~(12,104)~ = 2.26, P = 0.013, ω^2^ = 0.115; interaction: F~(12,~ ~104)~ = 3.08, P = 0.0009, ω^2^ = 0.177) caused by RS, when compared to the ACSF-stressed group. The Fisher's *post-hoc* point-to-point test is presented in the figure. ([**Figure 3**](#f3){ref-type="fig"}).

![**(A)** Representative recording of one CoCl~2~-treated and one vehicle-treated (ACSF) animal demonstrating the pressor and tachycardic response caused by the microinjection of CoCl~2~ (1 mM/100nl) into the DMH of rats at rest in their home-cages. The microinjection was performed at time -10 min. **(B)** Representative recording of one CoCl~2~-treated and one vehicle-treated (ACSF) animals subjected to one RS session illustrating the cardiovascular changes caused by this stress model. The RS session was started at time 0 min and finished at 60 min.](fphar-10-01547-g004){#f4}

Effect of Cocl~2~ Microinjection Into the DMH on the Neuroendocrine Response in Rats At the Home-Cage and Subjected to RS {#s3_3}
-------------------------------------------------------------------------------------------------------------------------

The two-way ANOVA indicated that RS, regardless of treatment, significantly increased corticosterone (condition: F~(1,~ ~20)~ = 63.45, P \< 0.0001, ω^2^ = 0.75, interaction: F~(1,20)~ = 0.42, P = 0.52, ω^2^ = 0) and oxytocin (condition: F~(1,21)~ = 33.42, P \< 0.0001, ω^2^ = 0.59 interaction: F~(1,21)~ = 0.23, P = 0.63) plasma levels, without affecting the vasopressin one (condition: F~(1,20)~ = 0.65, P = 0.42, interaction: ~(1,20)~ = 1.05, P = 0.31). In addition, the pretreatment with CoCl~2~ into the DMH indicated that DMH pretreatment with CoCl~2~ (1 mM/100 nl) (n = 6) in animals at rest in home-cage, significantly reduced the basal plasmatic levels of vasopressin (treatment: F~(1,~ ~20)~ = 5.05, P = 0.03, ω^2^ = 0.16), without affecting corticosterone (treatment: F~(1,~ ~20)~ = 1.65, P = 0.21) and oxytocin (treatment: F~(1,~ ~21)~ = 0.56, P = 0.46) levels, when compared to the ACSF home-cage group (n = 6) ([**Figure 5**](#f5){ref-type="fig"}).

![Corticosterone, vasopressin and oxytocin plasma concentrations over time before and during one RS session in rats with bilateral DMH pretreated with either vehicle (ACSF 100 nl n = 6) or CoCl~2~ (1 mM/100 nl n = 6). The RS session started at time 0 min and finished at 60 min. The dashed bars represent the naïve rats, white bars represents the DMH vehicle-treated (ACSF) rats, and the black bars represent DMH CoCl~2~-treated rats. Points represent the mean and bars the SEM. \*indicates significantly difference between stressed-group and home-cage group, (Two-way ANOVA, p \< 0.05). \# indicates significantly difference between CoCl~2~-treated and vehicle-treated animals, both at home-cage condition (unpaired *t* Student test, P \< 0.05).](fphar-10-01547-g005){#f5}

Discussion {#s4}
==========

The DMH is recognized as an important area involved in central cardiovascular control. In the present study, we investigated the role of DMH in the control of the autonomic and neuroendocrine responses during two situations: at rest in the home-cage, and during exposure to RS, a well-established animal model of stress.

First, to study the participation of DMH in the maintenance of cardiovascular tonus and neuroendocrine parameters, we microinjected CoCl~2~, an acute and reversible synapses blocker, into the DMH of rats at rest in their home-cages. CoCl~2~ is a pharmacological approach to blockade the nonspecific synaptic transmissions, by reversible blockade of calcium channels of the presynaptic membrane and consequent prevention of the neurotransmitters release ([@B19]). The microinjection of CoCl~2~ is an advantageous pharmacological tool to study the overall influence of a central area when compared to other inhibitors. The use of lidocaine, a local anesthetic, could block the local synapse transmission, but also the propagation of the action potencial by fibers of passage ([@B38]). The lesion of a brain area is permanent, irreversible and also affect the fibers of passage ([@B24]). The use of GABA~A~ antagonists could inhibit only the neurons that express GABA~A~ receptors ([@B26]).

A previous study demonstrated that microinjection of 1 mM CoCl~2~ into the medial prefrontal cortex was able to interfere with a functional response, the barorreflex, in a similar way to the microinjection of lidocaine in the same area ([@B34]), suggesting that this dose of CoCl~2~ is effective to blockade synaptic transmissions. Posteriorly, 1 mM CoCl~2~ was has been extensively used to study the involvement of brain areas in the neural circuitry of cardiovascular responses ([@B7]; [@B44]; [@B33]; [@B14]; [@B11]; [@B25]).

The blockade of DMH synaptic transmissions by the pretreatment with CoCl~2~ caused an increase in baseline BP, HR, without affecting the tail temperature, suggesting an inhibitory influence of the DMH on the cardiovascular tonus. Previous studies have demonstrated that microinjection of bicuculine, a GABA~A~ antagonist, into the DMH caused a robust increase in HR and a less prominent increase in BP ([@B39]; [@B2]; [@B37]). A possible explanation for the similarity of the results observed with the CoCl~2~ or bicuculine ([@B39]; [@B2]; [@B37]) microinjection could be that DMH overall output negatively modulates areas involved in the neurocircuitry of the cardiovascular control, as evidenced by the overall inhibition of the local neurotransmission by the pretreatment with CoCl~2~. In this way, the increase in BP and specially in the HR, which is observed after the microinjection of the GABA~A~ antagonist bicuculine, could suggest the existence of a facilitatory mechanism in the DMH that is negatively modulated by neurons expressing GABA~A~ in that nuclei. As discussed by [@B24] there are several differences in the mechanisms of the inhibition approach used to study the role of a central area. Although inhibition with CoCl~2~ would indicated the overall resulting vector from multiple local neurotransmissions, the actual influence exerted by a particular neurotransmission would only be evidenced with the used of selective antagonists, such as the case of bicuculine, when concerning the gabaergic neurotransmission.

In order to evaluate the possible DMH participation in neuroendocrine modulation under a rest condition in the home-cage, we microinjected CoCl~2~ bilaterally into the DMH and measured plasma levels of corticosterone, vasopressin and oxytocin. Interestingly, the microinjection of CoCl~2~ into the DMH decreased basal vasopressin plasmatic levels, but did not affect basal corticosterone and oxytocin, suggesting a facilitatory role of DMH on the vasopressin release under rest condition. Previous studies have reported a DMH participation in different neuroendocrine responses. The microinjection of muscimol, a GABA~A~ agonist, into the DMH increased the ACTH plasma levels ([@B16]), whereas DMH surgical lesion has been shown to decrease magnocellular vasopressin mRNA levels in the PVN ([@B18]), a result that corroborates the present findings with the inhibition of the DMH with CoCl~2~. This discrepancy of neuroendocrine results would take into account the different type of transmission inactivation caused by muscimol and by cobalt chloride or a DMH lesion. While cobalt and surgical lesions would silence overall DMH synaptic activity by either a presynaptic Ca^2+^ antagonism ([@B19]; [@B24]) or a physical lesion ([@B18]), the GABA~A~ agonist muscimol would mimic an increased gabaergic inhibitory influence on selective DMH neurons displaying GABA~A~ receptors ([@B27]); therefore, indicating that further studies are necessary to understand the influence played by individual neurotransmissions in the DMH on the cardiovascular modulation.

In a second set of experiments, we studied the possible involvement of DMH in the modulation of autonomic and neuroendocrine responses caused by acute exposure to RS. Animals were pretreated with CoCl~2~ or vehicle microinjected bilaterally into the DMH and then were subjected to RS, and results were compared with those observed in vehicle-treated animals. DMH inactivation by CoCl~2~ reduced the pressor and tachycardic response evoked by RS. Previous studies have reported that gabaergic inhibition of DMH, by local administration of muscimol, reduced the pressor and tachycardic response evoked by air jet stress ([@B40]; [@B9]; [@B42]; [@B8]; [@B1]). If the cardiovascular correlates of air jet and RS shares the same autonomic circuitry, the results from the use of muscimol ([@B40]; [@B9]; [@B42]; [@B8]; [@B1]) could indicate that DMH neurons under gabaergic influence are involved in the modulation of stress-evoked cardiovascular responses as a local facilitatory component in the neural circuitry. In the present study, the inactivation of the DMH with CoCl~2~ increased the baseline cardiovascular parameters at rest condition; however, the maximal RS-evoked BP an HR (raw values) increase was the same in vehicle-treated and cobalt-treated animals, and consequently, the change from baseline (ΔMAP and ΔHR) was smaller in the CoCl~2~-treated group when compared to the vehicle-treated one, a result that could suggest a DMH facilitatory influence on the cardiovascular response caused by RS. Alternatively, the attenuation of the RS-evoked cardiovascular response observed in this study could be explained by the baseline alteration caused by the CoCl~2~ microinjection into the DMH, and consequently the existence of a ceiling effect for RS-evoked cardiovascular responses. However, previous studies have demonstrated that the tachycardic ([@B44]; [@B6]; [@B13]) response could be still potentiated after the CoCl~2~ microinjection in different central nervous system areas, arguing the idea of the existence of a ceiling effect, and favoring the idea that DMH inhibition reduces the RS-evoked BP and HR responses. Nonetheless, further studies are necessary to clarify the issue.

Besides its involvement in cardiovascular modulation, the DMH is also recognized as a thermoregulatory structure. In this context, we found that inhibition of the DMH by local microinjection of CoCl~2,~ prevented the RS-evoked fall in tail temperature in rats, when compared to the vehicle-treated animals, suggesting that DMH plays a facilitatory role on the sympathetic control of tail artery territory, which is associated with the decrease of tail temperature in response to RS. The thermoregulatory role of the DMH can be justified by the neural input that DMH receives from the medial preoptic area (mPOA), a well-recognized thermoregulatory center ([@B45]; [@B16]). Supporting the idea of a DMH modulation of the tail temperature during RS, our group has reported previously that microinjection of CoCl~2~ into the mPOA impaired the reduction in tail temperature caused by this stress model ([@B11]), reinforcing the existence of a neuronal communication between these two important thermoregulatory centers, during the exposure to acute RS.

In relation to RS-evoked neuroendocrine responses, the increases in the plasma levels of corticosterone and oxytocin were not affected by the pretreatment of the DMH with CoCl~2~, when compared to the vehicle-stressed group. No changes in vasopressin plasma content were observed in either vehicle or CoCl~2~-treated animals, suggesting that DMH does not modulate the neuroendocrine response observed during the exposure to RS. Nonetheless, in a recent study, it has been reported that activation of the serotonergic neurotransmission in the DMH impaired the increase in costicosterone plasmatic levels caused by acute RS ([@B41]), thus suggesting that selective neurotransmissions in the DMH can modulate the neuroendocrine response caused by RS.

In conclusion, the results from the inactivation of DMH synaptic function by local microinjections of CoCl~2~ suggests the involvement of the DMH in the maintenance of cardiovascular tonus, playing an inhibitory influence on the BP and HR baseline under rest conditions at home cage, and a facilitatory influence on the baseline vasopressin release into circulation, without affecting the baseline tail temperature, corticosterone and oxytocin plasma levels under rest conditions at the home-cage. In addition, results indicating that DMH that inactivation with CoCl~2~ interfered with RS-evoked BP and HR increase, and prevented the RS-evoked reduction in tail temperature without affecting the RS-evoked increase in plasma corticosterone and oxytocin plasma levels, suggest the involvement of the DMH in the neural circuitry controlling RS-evoked cardiovascular responses, and clearly indicate that functional integrity of this area is essential for the generation of the to the RS-evoked fall in tail temperature.
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